Holen Sie sich die Stockscreener-App
2.555
7.81%
0.185
Schlusskurs vom Vortag:
$2.37
Offen:
$2.38
24-Stunden-Volumen:
412.53K
Relative Volume:
0.31
Marktkapitalisierung:
$22.94M
Einnahmen:
$93.76M
Nettoeinkommen (Verlust:
$-13.68M
KGV:
-0.9715
EPS:
-2.63
Netto-Cashflow:
$8.77M
1W Leistung:
+17.74%
1M Leistung:
+27.75%
6M Leistung:
+48.55%
1J Leistung:
-7.21%
1-Tages-Spanne:
$2.3526
$2.58
1-Wochen-Bereich:
$2.1534
$2.58
52-Wochen-Spanne:
$0.95
$2.87
Aytu Biopharma Inc Stock (AYTU) Company Profile
Firmenname
Aytu Biopharma Inc
Sektor
Telefon
(720) 437-6580
Adresse
7900 E. UNION AVENUE, DENVER
Vergleichen Sie AYTU mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.555 | 19.48M | 93.76M | -13.68M | 8.77M | -2.63 |
|
ZTS
Zoetis Inc
|
151.19 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.55 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.65 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
297.89 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-01 | Eingeleitet | Lake Street | Buy |
| 2025-06-30 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2021-03-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-05-29 | Eingeleitet | H.C. Wainwright | Buy |
Aytu Biopharma Inc Aktie (AYTU) Neueste Nachrichten
Aytu BioPharma Inc. Stock Analysis and ForecastAccelerated wealth expansion - jammulinksnews.com
What drives Aytu BioPharma Inc. stock priceFree Stock Market Mentorship - jammulinksnews.com
What analysts say about Aytu BioPharma Inc. stockUnstoppable trading performance - jammulinksnews.com
Lake Street Sees Big Upside for Aytu Biosciences (AYTU) After EXXUA Acquisition - Insider Monkey
11 Best High Return Penny Stocks to Buy Now - Insider Monkey
Is Aytu BioPharma Inc. a good long term investmentOver 200% growth - Jammu Links News
What makes Aytu BioPharma Inc. stock price move sharplyWeekly Big Movers - beatles.ru
Why Aytu BioPharma Inc. stock attracts strong analyst attentionDouble Profit With Half Risk - beatles.ru
How Aytu BioPharma Inc. stock performs during market volatilityTrending Stock Alert - Newser
Aytu BioPharma Completes $15 Million Debt Refinancing - ACCESS Newswire
Aytu BioPharma (NASDAQ:AYTU) Downgraded by Wall Street Zen to Buy - Defense World
Aytu Boosts Liquidity with Eclipse Loan Extension - MSN
Aytu BioPharma (NASDAQ:AYTU) Now Covered by Lake Street Capital - Defense World
Aytu BioPharma (AYTU): Lake Street Initiates Coverage with Buy Rating | AYTU Stock News - GuruFocus
Lake Street Initiates Aytu BioPharma at Buy With $8 Price Target - MarketScreener
Aytu BioPharma (NASDAQ:AYTU) Coverage Initiated by Analysts at Ascendiant Capital Markets - Defense World
AYTU: Ascendiant Capital Initiates Coverage with 'Buy' Rating | AYTU Stock News - GuruFocus
This Starbucks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome - ACCESS Newswire
AYTU SEC FilingsAytu Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aytu BioPharma (NASDAQ:AYTU) Upgraded by Wall Street Zen to Strong-Buy Rating - Defense World
15 Best Growth Stocks to Invest in for the Next 5 Years - Insider Monkey
Nobel Prize Contributor Joins Aytu to Lead $22B EXXUA Depression Drug Launch | AYTU Stock News - Stock Titan
Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM) - ACCESS Newswire
Aytu BioScience Expands Lending Agreement for EXXUA Launch - TipRanks
Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Significant Decline in Short Interest - Defense World
Insider Spends US$100k Buying More Shares In Aytu BioPharma - simplywall.st
CEO & Director of Aytu BioPharma Joshua Disbrow Buys 77% More Shares - Yahoo Finance
Transcript : Aytu BioPharma, Inc.Special Call - MarketScreener
Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock By Investing.com - Investing.com India
Insider Buying: Jarrett Disbrow Acquires Shares of Aytu BioPharm - GuruFocus
Insider Buying: Jarrett Disbrow Acquires Shares of Aytu BioPharma Inc (AYTU) - GuruFocus
Aytu Biopharma chief business officer buys $24,999 in stock By Investing.com - Investing.com South Africa
Aytu Biopharma chief business officer buys $24,999 in stock - Investing.com Australia
Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock - Investing.com Australia
AYTU BIOPHARMA Executives Increase Stake in Company - TradingView
Aytu BioPharma Closes $16.6 Mln Offering To Support EXXUA Launch For Major Depressive Disorder - Nasdaq
Aytu BioPharma Announces Closing of Upsized At the Market Public - GuruFocus
Finanzdaten der Aytu Biopharma Inc-Aktie (AYTU)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.09%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):